The Injective price has arrived at a level that could decide whether this recovery has real legs. After a descending triangle breakout, $INJ is now testing the 200-day EMA around $5, just as Injective announced a major expansion of its tokenization infrastructure. Clear $5, and $5.50 followed by $6 become the obvious targets. Fail here, and the chart could get ugly again.
Injective Pushes RWA Infrastructure Into Markets #
The latest development goes well beyond another tokenization announcement. POSCO International and LG CNS launched a pilot using live trade data and real commercial receivables on Injective.
AI agents reviewed Letters of Credit and supporting documents, while receivables were issued as permissioned onchain assets with compliance controls embedded into the infrastructure.
That puts real commercial activity alongside Injective’s broader push into institutional finance. The network says it has already tokenized institutional funds, public equities, trade receivables and pre-IPO shares involving companies such as SpaceX and OpenAI.
Then there’s the regulatory angle. Injective says it is now an SEC-registered transfer agent, making it the first layer 1 blockchain to combine native RWA infrastructure with regulated recordkeeping capabilities for American capital markets.
AI And Compliance Become Part Of The Stack #
The pitch is becoming increasingly straightforward, combining RWA infrastructure, AI-powered finance and regulatory rails within one network.
That’s a much bigger proposition than simply putting financial assets onchain. Injective is positioning the network as infrastructure for compliant capital markets that can serve institutions as well as everyday users.
Whether the market ultimately rewards that ambition is another matter entirely. Crypto has never been particularly generous about paying for fundamentals before demand arrives.
Injective Price Faces Its First Major Test #
For now, the Injective price has its own job to do. The recent descending triangle breakout has pushed $INJ price directly into the 200-day EMA near $5. A clean breakout and sustained move above that level could open the path towards $5.50 and then $6. But rejection would tell a different story, potentially sending $INJ back towards $4 or lower.
So despite the expanding RWA narrative, the Injective price still needs to prove itself on the chart. $5 is the line in the sand.